Plus Therapeutics' Subsidiary CNside Diagnostics Announces New Payer Coverage Agreement With Blue Shield Of California, Effective April 2026, Providing Reimbursement For Its CNside Cerebrospinal Fluid Tumor Cell Enumeration Assay For Metastatic Central Nervous System Cancer Patients